AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
benfotiamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 308 | 22457-89-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Onychomycosis | 120.99 | 31.67 | 48 | 3525 | 37328 | 90587546 |
| Onychomadesis | 117.98 | 31.67 | 50 | 3523 | 45948 | 90578926 |
| Injection site reaction | 98.49 | 31.67 | 55 | 3518 | 92025 | 90532849 |
| C-reactive protein abnormal | 65.62 | 31.67 | 48 | 3525 | 127381 | 90497493 |
| Ill-defined disorder | 63.76 | 31.67 | 55 | 3518 | 184836 | 90440038 |
| Rheumatic fever | 62.02 | 31.67 | 50 | 3523 | 153071 | 90471803 |
| C-reactive protein increased | 60.61 | 31.67 | 53 | 3520 | 181336 | 90443538 |
| Type 2 diabetes mellitus | 59.27 | 31.67 | 55 | 3518 | 203189 | 90421685 |
| Therapeutic product effect incomplete | 57.56 | 31.67 | 53 | 3520 | 193843 | 90431031 |
| Underdose | 56.97 | 31.67 | 32 | 3541 | 53985 | 90570889 |
| Sleep disorder | 49.05 | 31.67 | 49 | 3524 | 197981 | 90426893 |
| Therapeutic product effect decreased | 45.02 | 31.67 | 55 | 3518 | 277516 | 90347358 |
| Psoriatic arthropathy | 41.56 | 31.67 | 48 | 3525 | 228287 | 90396587 |
| Pericarditis | 39.76 | 31.67 | 51 | 3522 | 270100 | 90354774 |
| Wound | 39.66 | 31.67 | 54 | 3519 | 302926 | 90321948 |
| Treatment failure | 38.02 | 31.67 | 53 | 3520 | 303875 | 90320999 |
| Systemic lupus erythematosus | 36.47 | 31.67 | 57 | 3516 | 361839 | 90263035 |
| Synovitis | 34.71 | 31.67 | 53 | 3520 | 329699 | 90295175 |
| Product use in unapproved indication | 33.93 | 31.67 | 53 | 3520 | 336183 | 90288691 |
| Confusional state | 32.39 | 31.67 | 56 | 3517 | 386149 | 90238725 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Onychomycosis | 126.29 | 39.13 | 51 | 4647 | 38480 | 110546121 |
| Onychomadesis | 121.22 | 39.13 | 52 | 4646 | 45611 | 110538990 |
| Injection site reaction | 98.97 | 39.13 | 56 | 4642 | 89014 | 110495587 |
| Capillaritis | 85.40 | 39.13 | 20 | 4678 | 2419 | 110582182 |
| Therapeutic product effect incomplete | 81.67 | 39.13 | 71 | 4627 | 223734 | 110360867 |
| Sleep disorder | 76.48 | 39.13 | 65 | 4633 | 198579 | 110386022 |
| Ill-defined disorder | 74.45 | 39.13 | 58 | 4640 | 156795 | 110427806 |
| Rheumatic fever | 73.10 | 39.13 | 52 | 4646 | 122527 | 110462074 |
| Type 2 diabetes mellitus | 70.28 | 39.13 | 59 | 4639 | 177173 | 110407428 |
| C-reactive protein abnormal | 68.22 | 39.13 | 51 | 4647 | 129644 | 110454957 |
| Antineutrophil cytoplasmic antibody positive | 66.35 | 39.13 | 19 | 4679 | 5057 | 110579544 |
| Conjunctivitis allergic | 64.70 | 39.13 | 20 | 4678 | 6911 | 110577690 |
| Mite allergy | 59.51 | 39.13 | 18 | 4680 | 5785 | 110578816 |
| Mycotic allergy | 59.06 | 39.13 | 18 | 4680 | 5936 | 110578665 |
| Dust allergy | 58.92 | 39.13 | 18 | 4680 | 5983 | 110578618 |
| Spirometry abnormal | 56.15 | 39.13 | 17 | 4681 | 5480 | 110579121 |
| C-reactive protein increased | 56.11 | 39.13 | 57 | 4641 | 217862 | 110366739 |
| Neuritis | 55.21 | 39.13 | 18 | 4680 | 7381 | 110577220 |
| Total lung capacity abnormal | 54.76 | 39.13 | 16 | 4682 | 4567 | 110580034 |
| Pulmonary vasculitis | 53.19 | 39.13 | 17 | 4681 | 6543 | 110578058 |
| Underdose | 52.41 | 39.13 | 33 | 4665 | 63521 | 110521080 |
| Systemic lupus erythematosus | 52.21 | 39.13 | 59 | 4639 | 254279 | 110330322 |
| Wound | 49.16 | 39.13 | 55 | 4643 | 234382 | 110350219 |
| Eosinophilic granulomatosis with polyangiitis | 48.73 | 39.13 | 18 | 4680 | 10668 | 110573933 |
| Pericarditis | 48.70 | 39.13 | 53 | 4645 | 219061 | 110365540 |
| Psoriatic arthropathy | 47.98 | 39.13 | 50 | 4648 | 196711 | 110387890 |
| Pemphigus | 47.86 | 39.13 | 52 | 4646 | 214518 | 110370083 |
| Therapeutic product effect decreased | 47.31 | 39.13 | 55 | 4643 | 244261 | 110340340 |
| Normochromic normocytic anaemia | 45.22 | 39.13 | 18 | 4680 | 13039 | 110571562 |
| Forced expiratory volume decreased | 45.06 | 39.13 | 18 | 4680 | 13158 | 110571443 |
| Synovitis | 43.81 | 39.13 | 56 | 4642 | 274036 | 110310565 |
| Neurological symptom | 42.12 | 39.13 | 18 | 4680 | 15590 | 110569011 |
| Product use issue | 41.13 | 39.13 | 58 | 4640 | 311637 | 110272964 |
| Pulmonary alveolar haemorrhage | 40.79 | 39.13 | 19 | 4679 | 20131 | 110564470 |
| Treatment failure | 40.20 | 39.13 | 54 | 4644 | 277180 | 110307421 |
| Respiratory symptom | 39.55 | 39.13 | 17 | 4681 | 14928 | 110569673 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A11DA03 | ALIMENTARY TRACT AND METABOLISM VITAMINS VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 Vitamin B1, plain |
| CHEBI has role | CHEBI:22586 | antioxidant |
| CHEBI has role | CHEBI:50267 | protective agent |
| CHEBI has role | CHEBI:50733 | nutraceutical |
| CHEBI has role | CHEBI:50847 | immunological adjuvant |
| CHEBI has role | CHEBI:72470 | provitamin B<small><sub>1</sub></small> |
Related Drugs by ATC class:
A11DA Vitamin B1, plain 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.16 | acidic |
| pKa2 | 6.98 | acidic |
| pKa3 | 7.59 | Basic |
| pKa4 | 0.96 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4028227 | VUID |
| N0000177939 | NUI |
| D01255 | KEGG_DRUG |
| 18891 | RXNORM |
| C0053116 | UMLSCUI |
| CHEBI:41039 | CHEBI |
| BFT | PDB_CHEM_ID |
| CHEMBL4303665 | ChEMBL_ID |
| DB11748 | DRUGBANK_ID |
| 1300 | INN_ID |
| Y92OUS2H9B | UNII |
| 3032771 | PUBCHEM_CID |
| 23417 | MMSL |
| 366760 | MMSL |
| d08940 | MMSL |
| 4028227 | VANDF |
| 005583 | NDDF |
| 703399007 | SNOMEDCT_US |
| 704989003 | SNOMEDCT_US |
Pharmaceutical products:
None